Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus Sep 8, 2021 08:00AM
Catabasis Pharmaceuticals to Present Data from the MoveDMD® trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 71st Annual Meeting May 2, 2019 08:00AM
Catabasis Pharmaceuticals to Report First Quarter 2019 Financial Results and Recent Corporate Developments on Tuesday, May 14th Apr 30, 2019 08:00AM
Catabasis Pharmaceuticals to Present at Oppenheimer’s 29th Annual Healthcare Conference Mar 13, 2019 08:00AM
Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Developments on Thursday, March 14 Feb 28, 2019 08:00AM


Feb 19, 2019 08:00AM Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy
Feb 14, 2019 08:00AM Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors
Feb 6, 2019 09:04AM Catabasis Pharma (CATB) Prices $20M Public Offering of Common Stock and Warrants
Feb 6, 2019 09:00AM Catabasis Pharmaceuticals Announces Pricing of $20 Million Underwritten Public Offering
Feb 5, 2019 04:44PM Catabasis Pharma (CATB) Plans Underwritten Public Offering
Feb 5, 2019 04:01PM Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering
Jan 4, 2019 08:03AM Catabasis Pharma (CATB) Announces Gregg Lapointe to Board
Jan 4, 2019 08:00AM Catabasis Pharmaceuticals Appoints Gregg Lapointe to its Board of Directors
Jan 3, 2019 08:17AM Catabasis Pharma (CATB) Reports Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy Progress Update; Announces Additional Trial Sites Open for Enrollment
Jan 3, 2019 08:08AM Catabasis Pharmaceuticals Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy Progress Update and Additional Trial Sites Open for Enrollment
Dec 24, 2018 08:01AM Catabasis Pharma (CATB) Announces 1-for-10 Reverse Stock Split
Dec 24, 2018 08:00AM Catabasis Pharmaceuticals Announces Reverse Stock Split
Nov 27, 2018 08:06AM Catabasis Pharma (CATB) Announces Publication of Phase 1 Clinical Results of Edasalonexent (CAT-1004) in DMD
Nov 27, 2018 08:00AM Catabasis Pharmaceuticals Announces Publication of Phase 1 Clinical Results of Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy
Nov 13, 2018 08:05AM Catabasis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Reviews Business Progress
Nov 13, 2018 07:45AM Catabasis Pharmaceuticals Announces Collaboration with the University of Texas Southwestern to Explore the Potential Benefits of Edasalonexent on Cardiac Function in Duchenne and Becker Muscular Dystr
Oct 30, 2018 08:00AM Catabasis Pharmaceuticals to Report Third Quarter 2018 Financial Results and Recent Corporate Developments on Tuesday, November 13
Oct 3, 2018 08:00AM Catabasis Pharmaceuticals Presents Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne Muscular Dystrophy at the World Muscle Society Congress
Sep 25, 2018 08:03AM Catabasis Pharma (CATB) Commences hase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy
Sep 25, 2018 08:00AM Catabasis Pharmaceuticals Initiates Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy
Dec 6, 2017 02:00AM Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day
Dec 6, 2017 01:00AM Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness Day
Nov 16, 2016 01:00PM Catabasis Pharmaceuticals, Inc. (Nasdaq: CATB) to Ring The Nasdaq Stock Market Closing Bell
Sep 23, 2016 12:52PM Unusual 11 Mid-Day Movers 9/23: (IMPV) (BLRX) (TWTR) Higher; (ENPH) (APPS) (RAVE) Lower
Jun 14, 2016 09:00AM CureDuchenne and Catabasis Pharmaceuticals to Host a Webinar to Review Information on Edasalonexent (CAT-1004) and the MoveDMDSM Trial on June 22, 2016